Website Header with Language Selector and Dropdowns
Image

Naphthyridine Carboxylic Acid Analog


Catalog Number: CL-GMF-09
CAS No.: 100361-18-0
Mol.F: C12H8ClFN2O3
Mol.W: 282.7
Inv. Status: Custom Synthesis

Chemical Name: 7-Chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (as per USP).

Country of Origin: India

Product Category: Gemifloxacin Impurities


Naphthyridine Carboxylic Acid Analog is identified by CAS No. 100361-18-0 and is chemically known as 7-Chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (as per USP).

Naphthyridine Carboxylic Acid Analog is provided with comprehensive characterization data in accordance with regulatory guidelines. It is suitable for use in analytical method development, method validation (AMV), Quality Control (QC) applications for Abbreviated New Drug Applications (ANDA) and commercial production of Gemifloxacin.

Page Keywords: Buy Naphthyridine Carboxylic Acid Analog | Purchase Naphthyridine Carboxylic Acid Analog | Naphthyridine Carboxylic Acid Analog suppliers | Naphthyridine Carboxylic Acid Analog manufacturers | Naphthyridine Carboxylic Acid Analog price | Naphthyridine Carboxylic Acid Analog Importer | Naphthyridine Carboxylic Acid Analog Exporter

Enquiry Now

Personal Details

Product Details

Related Products

CAT No: CL-GMF-03
CAS No: 284474-14-2
Mol Wt: 143.2
Mol F: C6H13N3O
Inv. Status: Custom Synthesis
CAT No: CL-GMF-06
CAS No: 616827-84-0
Mol Wt: 635.6
Mol F:  C30H27F2N7O7
Inv. Status: Custom Synthesis
CAT No: CL-GMF-07
CAS No: 210353-54-1
Mol Wt: 389.4
Mol F: C18H20FN5O4
Inv. Status: Custom Synthesis
CAT No: CL-GMF-02
CAS No: NA
Mol Wt: 360.3 : 96.1
Mol F: C17H17FN4O4 : CH4O3S
Inv. Status: Custom Synthesis
CAT No: CL-GMF-01
CAS No: 210353-53-0
Mol Wt: 389.4 : 96.1
Mol F: C18H20FN5O4 : CH4O3S
Inv. Status: Custom Synthesis
CAT No: CL-GMF-08
CAS No: NA
Mol Wt: 360.3 : 96.1
Mol F: C17H17FN4O4 : CH4O3S
Inv. Status: Custom Synthesis
Subscribe for news letter:
  

© Cleanchem Laboratories LLP. All Rights Reserved.